Akebia’s Vadadustat Receives FDA Complete Response Letter

Akebia Therapeutics will have to conduct a new clinical trial if it wants to move its kidney disease drug vadadustat forward, the FDA said in a Complete Response Letter (CRL) denying approval for the investigational drug.
Source: Drug Industry Daily